Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Brain Health
- Life Span Health
- Infectious/ Immunological Health
- Specialized Health
- Metabolic Health
Fingerprint
Dive into the research topics where Gary Kobinger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Pandemic Preparedness: Biocontainment Facility upgrade and Integration at UTMB/Galveston National Laboratory
Kobinger, G. (PI)
National Institute of Allergy and Infectious Diseases
9/16/22 → 2/28/25
Project: Research project
-
EBOV002, a Phase 1b, Placebo-controlled, Single-center Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine
Kobinger, G. (PI)
11/1/22 → 1/19/23
Project: Research project
-
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers
Kobinger, G. (PI)
9/15/22 → 11/17/22
Project: Research project
-
Sphingosine Kinases Promote Ebola Virus Infection and Can Be Targeted to Inhibit Filoviruses, Coronaviruses, and Arenaviruses Using Late Endocytic Trafficking to Enter Cells
Stewart, C. M., Bo, Y., Fu, K., Chan, M., Kozak, R., Apperley, K. Y. P., Laroche, G., Daniel, R., Beauchemin, A. M., Kobinger, G., Kobasa, D. & Côté, M., May 12 2023, In: ACS Infectious Diseases. 9, 5, p. 1064-1077 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
Azizi, H., Knapp, J. P., Li, Y., Berger, A., Lafrance, M. A., Pedersen, J., de la Vega, M. A., Racine, T., Kang, C. Y., Mann, J. F. S., Dikeakos, J. D., Kobinger, G. & Arts, E. J., May 2023, In: Vaccines. 11, 5, 977.Research output: Contribution to journal › Article › peer-review
Open Access -
Human and Livestock Surveillance Revealed the Circulation of Rift Valley Fever Virus in Agnam, Northern Senegal, 2021
Mhamadi, M., Badji, A., Barry, M. A., Ndiaye, E. H., Gaye, A., Ndiaye, M., Mhamadi, M., Touré, C. T., Ndiaye, O., Faye, B., Diop, B., Ndiaye, M., Fall, M., Diouf, A. M., Sagne, S. N., Loucoubar, C., Fausther-Bovendo, H., Ara, H., Sall, A. A. & Kobinger, G. & 3 others, , Feb 2023, In: Tropical Medicine and Infectious Disease. 8, 2, 87.Research output: Contribution to journal › Article › peer-review
Open Access -
SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
de La Vega, M. A., Polychronopoulou, E., XIII, A., Ding, Z., Chen, T., Liu, Q., Lan, J., Nepveu-Traversy, M. E., Fausther-Bovendo, H., Zaidan, M. F., Wong, G., Sharma, G. & Kobinger, G. P., 2023, In: Emerging Microbes and Infections. 12, 1, e2169198.Research output: Contribution to journal › Article › peer-review
Open Access -
A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
Gomez, A. M., Babuadze, G., Plourde-Campagna, M. A., Azizi, H., Berger, A., Kozak, R., de La Vega, M. A., Xiii, A., Naghibosadat, M., Nepveu-Traversy, M. E., Ruel, J. & Kobinger, G. P., Dec 2022, In: npj Vaccines. 7, 1, 172.Research output: Contribution to journal › Article › peer-review
Open Access
Press/Media
-
WHO statement on COVID-19 vaccine
Kobinger, G., Brasel, T. & Tseng, C.-T.
4/14/20
1 item of Media coverage
Press/Media: Expert Comment
-
Public statement for collaboration on COVID-19 vaccine development
Kobinger, G., Brasel, T. & Tseng, C.-T.
4/13/20
1 item of Media coverage
Press/Media: Expert Comment